Search

Your search keyword '"Zuur, Charlotte L."' showing total 233 results

Search Constraints

Start Over You searched for: Author "Zuur, Charlotte L." Remove constraint Author: "Zuur, Charlotte L."
233 results on '"Zuur, Charlotte L."'

Search Results

4. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

5. A pan-cancer analysis of the microbiome in metastatic cancer

8. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

9. The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

10. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

11. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

15. Uncoupling DNA damage from chromatin damage to detoxify doxorubicin

20. The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

22. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

23. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

26. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

29. Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment

30. Optimizing Wound Care after Surgery of the Head and Neck: A Review of Dressing Materials.

31. Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors

32. Abstract 5786: Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer

33. Abstract 2281: Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment

37. Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma

38. Talimogene laherparepvec monotherapy for head and neck melanoma patients

39. Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma

40. The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.

41. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma:Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

42. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients:A systematic review and meta-analysis

43. Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma

44. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

46. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

48. Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes

Catalog

Books, media, physical & digital resources